medigraphic.com

2001, Number S1

<< Back Next >>

Arch Cardiol Mex 2001; 71 (S1)

Advances in the medical treatment of heart failure

López ME

Language: Spanish
References: 24
Page: 95-101
PDF size: 50.95 Kb.


ABSTRACT

Heart failure is one of the most important diseases in the recent years. Because of the advances in the cardiological practice, it can be identified frequently nowing much better pathophisiological mechanism and the investigation of different drugs for the improvement in sintomatology and the functional class of this patients. The first step is taking care about the diet, wich it has to be sodium free, a restrictive about intake. The second step is the use of diuretics and digitalis that has been used for many years. About the new treatment in the medical therapy is the point that we analyze in the present work and we think that in the future this alternatives will be much better and incorporated to the basic therapeutics.


REFERENCES

  1. MINIATI D, HUNT S, ROBBINS R: Treatment options for patients with severe myocardial failure: A review of the latest Technology. ACC Curr J Rev 1999; 8: 44-48.

  2. WAGONER LE, WALSH RA: Inotropic therapy for systolic heart failure. Compr Ther 1995; 21: 367-77.

  3. KIESO H, SILVER M: Newer inotropic agents for descompensated heart failure. ACC Curr J Rev 1999; 8: 35-38.

  4. PACKER M, CARVER JR, RODEHEFFER RJ, IVANHOE RJ, DIBIANCO R, ZELDIS FM, ET AL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75.

  5. STEVENSON LW: Inotropic Therapy for heart failure. N Engl J Med 1998; 339: 1848-50.

  6. COHN J. GOLDSTEIN SO, GREENBERG BH: A dose dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-16.

  7. NIELSEN-KUDSK JE, ALDERSHVILE J: Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovascular Pharmacol 1995; 26 (Suppl 1): S77-84.

  8. LEE JA, ALLEN DG: Calcium sensitizers: Mechanism of action and potential usefulness as inotropes. Cardiovasc Res 1997; 36: 10-20.

  9. KUBO SH: Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology 1997; 88 (Suppl 2): 21-27.

  10. VELI-PEKKA H, PEUHKURINEN K, NIEMINEN M, NIEMELA M, SUNBEGR S: Oral Levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 1999; 83: 4 (I)-8 (I).

  11. LILLEBERG J, NIEMINEN MS, AKKILA J, HEIKKILA L, KUITUNEN A, LEHTONEN L, ET AL: Effects of a new calcium sensitizer, levosimendan on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660-68.

  12. Hosenpud J for The Oral Levosimendan Group: Levosimendan, a novel Myofilament calcium sensitizer allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 1999; 83: 9 (I)-11 (I).

  13. FOLLÁTH F, HINKKA S, JAGER D, HANJOG J, MITROVIC D, PAPP JG, ET AL: Dose Ranging and safety with intravenous levosimendan in low output heart failure: Experience in Three pilot studies and Outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol 1999; 83: 21 (I)-25 (I).

  14. TRIPPODO NC, FOX M, MONTICELLO TM: Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition (Abst). Circulation 1998; 98 Suppl I :I-781.

  15. MC CLEAN D, IKRAM H, GARLICK A, RICHARDS M, NICHOLLS G, CROZIER I: The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. JACC 2000; 36: 479-86.

  16. ELSNER D, MUNTZE A, KROMER EP: Effectiveness of endopetidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70: 494-98

  17. MORKIN E, PENNOCK G, RAYA T, BAHL J, GODLMAN S: Development of a thyroid hormone analogue for the treatment of congestive heart failure. Thyroid 1996; 6: 521-6.

  18. ROSS J: Growth hormone, cardiomyocyte contractile reserve, and heart failure. Circulation 1999; 99: 15-17.

  19. OLIVETTI G, ABBI R, QUAINI F: Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141

  20. HALL SA, CIGARROA CG, MARCOUX L, RISSER RC, GRAYBURN PA, EICHHORN EJ: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta adrenergic blockade. J. Am Coll Cardiol 1997; 25: 1154-61.

  21. O CONNOR CH, GATTIS W, SWEDBERG ET ALT: Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 1998; 135: S249-263

  22. PACKER M, O CONNOR CM, GHALI JK, PRESSLER ML, CARSON PE, BELKIN RN: For the prospective randomized amlodipine survival evaluation study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.

  23. PITT B, SEGAL R, MARTÍNEZ FA: On behalf of the ELITE study investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study ELITE). Lancet 1997; 349: 747-52

  24. The digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33




2020     |     www.medigraphic.com